ライフサイエンスコーパス: EACA

1 EACA potently inhibited the binding of Glu-Pg to SK (K(i

2 with the ligands epsilon-aminocaproic acid (EACA) and trans-4-(aminomethyl)cyclohexane-1-carboxylic

3 ic acid (TXA) and epsilon-aminocaproic acid (EACA) are structurally similar to the inhibitory neurotr

4 oading dose of 5 grams of aminocaproic acid (EACA) intravenously 3 hours prior to the surgery.

5 g high amounts of epsilon-aminocaproic acid (EACA) provides a detailed and robust charge heterogeneit

6 ding constants of epsilon-aminocaproic acid (EACA), 7-aminoheptanoic acid (7-AHpA), and trans-(aminom

7 activation, e.g., epsilon-aminocaproic acid (EACA), or plasminogen antiserum.

8 Treatment with epsilon-aminocaproic acid (EACA), which inhibits plasmin activation, reduces tumor

9 analogues such as epsilon-aminocaproic acid (EACA).

10 anded and ligand [epsilon-aminocaproic acid (EACA)] bound modes and the structure of recombinant KIV-

11 ide-chain mimic, epsilon amino caproic acid (EACA), enhances the activation of Pg by urinary-type and

12 cinoma (ESCC) and esophageal adenocarcinoma (EACA) and 100% in metastasis, but no EpCAM overexpressio

13 overall molecular tumbling for both apo and EACA-bound K1(Pg).

14 Here we demonstrate that TXA and EACA are competitive antagonists of glycine receptors in

15 auses seizures, we hypothesized that TXA and EACA inhibit the activity of glycine receptors.

16 In assays simulating substrate binding, EACA also potently inhibited the binding of Glu-Pg to th

17 Both EACA structures were in the embedded binding mode utiliz

18 he Lp(a) was found to resist dissociation by EACA (0.2 M).

19 rogression and inhibition of this process by EACA may be beneficial as adjunct therapy.

20 he first dimension is based on a generic CZE(EACA) method in a fused silica capillary.

21 a promising tool for this purpose; however, EACA is incompatible with electrospray.

22 The KIV-10/M66, KIV-10/M66/EACA, and KIV-10/T66/EACA molecular structures are highl

23 Addition of EACA resulted in increases (approximately 12 degrees C)

24 rom the similar geometries of the binding of EACA and AMCHA, it appears that the kon is an important

25 uanidinium group close to the carboxylate of EACA to assist R71 in stabilizing the anionic group of t

26 A and r-[W63S]-K2tPA, high concentrations of EACA had little effect on the Tm of thermal denaturation

27 ngles in mediating the inhibitory effects of EACA: mini-Pg which lacks kringles 1-4 of Glu-Pg and mic

28 t the beginning of the extractions 1 gram of EACA per hour continuous infusion and a 6 pack of platel

29 binding mode, where only the amino group of EACA interacted with the anionic center of the LBS.

30 groove parallel to the expected position of EACA toward the anionic center (D55/D57) and makes a sal

31 A similar proportion of EACA resistant binding of Lp(a) was found with endotheli

32 KIV-10/M66, KIV-10/M66/EACA, and KIV-10/T66/EACA molecular structures are highly isostructural, indi

33 The KIV-10/T66/EACA structure determined in this work differs from one

34 human population) was reexamined (KIV-10/T66/EACA).

35 Taken together, these studies indicate that EACA inhibits Pg activation by blocking activator comple

36 e mechanism of this inhibition revealed that EACA (IC(50) 10 microM) also potently blocked amidolytic

37 tPA and r-[W63Y]K2tPA, a result showing that EACA stabilized the native conformations adopted by thes

38 The EACA resistant binding of Lp(a) was time and concentrati

39 In addition, the EACA liganded structure of a sequence polymorph (M66T in

40 splacement of three water molecules from the EACA binding groove and a movement of R35 bringing the g

41 igher binding energy of AMCHA as compared to EACA.

42 ter binding of AMCHA to Klpg, as compared to EACA.